Stockscreener 앱 받기
0.9389
3.36%
0.0305
시장 영업 전:
.94
0.0011
+0.12%
Adicet Bio Inc 주식(ACET)의 최신 뉴스
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by Jane Street Group LLC - Defense World
Geode Capital Management LLC Increases Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
Adicet Bio Advances First Gamma Delta CAR T Cell Therapy for Solid Tumors, Expands Autoimmune Trial - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Stake Reduced by State Street Corp - Defense World
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - Yahoo Finance
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio begins trial for kidney cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
Adicet Bio begins trial for kidney cancer therapy - Investing.com
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace
ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada
Adicet Bio names new Chief Medical Officer By Investing.com - Investing.com Australia
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - BioSpace
Adicet Bio Names Dr. Julia Maltzman As Chief Medical Officer - Contract Pharma
Adicet Bio names new Chief Medical Officer - Investing.com
Adicet Bio Names Dr. Julia Maltzman as Chief Medical Officer - Contract Pharma
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Canada
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1% - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces CAR-T challenges - Investing.com
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Rises By 6.1% - MarketBeat
Adicet Bio Awards New Employee Stock Options at $1.13 Per Share in Inducement Grant | ACET Stock News - StockTitan
Adicet Bio clears debt with Banc of California By Investing.com - Investing.com South Africa
Adicet Bio clears debt with Banc of California - Investing.com India
Adicet Bio Clears Debts with Banc of California - TipRanks
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Has $56,000 Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio, Inc. Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Marketscreener.com
Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq
Adicet Bio begins trial for innovative cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks
Adicet Bio begins trial for innovative cancer therapy - Investing.com
4.81%
자본화:
|
볼륨(24시간):